You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

 

Online download statistics by month:

Online download statistics by month: December 2019 to April 2026

AbstractFullPdf
Dec 2019330
Jan 2020880
Feb 202021212
Mar 202026261
Apr 202013133
May 202037379
Jun 202026264
Jul 2020161614
Aug 202012129
Sep 2020313129
Oct 2020272723
Nov 2020181812
Dec 2020232315
Jan 202116169
Feb 2021161616
Mar 2021292932
Apr 2021222110
May 2021191913
Jun 2021333322
Jul 2021353512
Aug 202119197
Sep 2021222218
Oct 2021272730
Nov 2021232223
Dec 2021232314
Jan 2022303212
Feb 2022172014
Mar 202220209
Apr 2022242414
May 2022192118
Jun 202218188
Jul 202227289
Aug 2022242411
Sep 2022414121
Oct 2022313117
Nov 2022323314
Dec 202231318
Jan 202324259
Feb 2023202011
Mar 2023272712
Apr 202312128
May 2023202012
Jun 202322227
Jul 2023303114
Aug 2023363625
Sep 202315152
Oct 2023262611
Nov 202319193
Dec 2023212110
Jan 2024313111
Feb 2024414114
Mar 2024313115
Apr 2024252612
May 2024181814
Jun 202416169
Jul 202443436
Aug 2024272789
Sep 2024252518
Oct 2024313116
Nov 2024394019
Dec 2024222517
Jan 2025313110
Feb 202522229
Mar 2025414128
Apr 202539399
May 202560260450
Jun 2025444414
Oct 2025001
Feb 2026110
Apr 2026110
Total22612277967